2018 American Transplant Congress
Predictive Value of mRECIST in HCC Response to the Neoadjuvant Locoregional Therapies and Prognosis Affected by the Peak AFP Level before Liver Transplantation
PURPOSE: The modified response evaluation criteria in solid tumors (mRECIST) has been used to assess the response of hepatocellular carcinoma (HCC) to locoregional therapy (LRT)…2018 American Transplant Congress
Malignancies in Kidney Transplant Recipients: A Long-Term Observational Study
Nephrology and Internal Intensive Care, Charite Universitaetsmedizin Berlin, Berlin, Germany.
Background: Previous studies have shown increased incidence of malignancies in patients after kidney transplantation. However, most of the existing data on post-transplant malignancies is limited…2018 American Transplant Congress
A Novel Nomogram-Based Approach for Defining the Effect of Transplantation on Cancer Recurrence Risk
1U of Cincinnati, Cincinnati; 2Cleveland Clinic, Cleveland.
The effect of transplantation on renal cell cancer (RCC) recurrence risk has not yet been precisely defined. Validated nomograms for predicting RCC recurrence risk (viz,…2018 American Transplant Congress
Liver Transplantation for Patients with Hepatocellular Carcinoma Presenting beyond Milan Criteria: Analysis of 789 Patients from the US Multicenter HCC Transplant Consortium
Objective: OPTN has recently approved MELD prioritization for HCC patients beyond Milan Criteria (MC) who are downstaged (DS) with locoregional therapy (LRT) prior to liver…2017 American Transplant Congress
Recurrent HCC After Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation.
Background:Liver resection (LR) and radiofrequency ablation (RFA) represent curative therapies for early stages of hepatocellular carcinoma (HCC). If tumour recurrence occurs, salvage liver transplant (SLT)…2017 American Transplant Congress
Pre-TACE Immune Status Correlates with Treatment Response and Tumor Biology in HCC as a Bridge to Transplant.
Purpose:Immune factors are pivotal against disease progression after transplant in hepatocellular carcinoma (HCC). With chemoembolization (TACE) as a bridge to liver transplant, this study compares…2017 American Transplant Congress
Serum AFP Greater Than 200 ng/ml as a Predictor for Low Survival in Patients with Hepatocelullar Carcinoma Recurrence in a Brazilian Multicentric Study.
Introduction: Liver transplantation (LT) is the only potential curative treatment for hepatocellular carcinoma (HCC) with recurrence (HCC-R) diagnosed in 16%. Aim: The objective of this…2017 American Transplant Congress
Very Long Term Graft Survival. Forecasts Factors.
Nephrology, Hospital Ramon y Cajal, Madrid, Spain
Introduction: Kidney transplantation is the best treatment for end-stage renal failure. Between 2 and 5% of transplanted grafts are lost each year and only a…2017 American Transplant Congress
Impact of Polymorphisms of UGT 1 A9 on the Prognosis of Renal Transplant Patients. Association with Digestive Tumors.
Nephrologist, Hospital Clinico San Carlos, Madrid, Spain
The aim of this study was to evaluate the distribution of UGT1A9 promoter region T-275A and C-2152T single nucleotide polymorphisms (SNPs) in stable transplant patients…2017 American Transplant Congress
HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence.
University of Alberta, Edmonton, AB, Canada
Background: Recent advances in the direct-acting antiviral (DAA) treatment of HCV have lead to high rates of HCV eradication, even in patients with decompensated cirrhosis.…
American Transplant Congress abstracts